17 completed, 1 terminated. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 17, Terminated 1 |
Follow Duration of Therapy: new trials by email Literature Review of Duration of Therapy trials Research Report on Duration of Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days, Comparator: amikacin / Duration of Treatment: 3 Days, Comparator: tazocin / Duration of Treatment: 3 Days - Infection, Pneumonia | Phase 4 | Completed | Merck Sharp & Dohme LLC | 120 | 2006-11-01 | 2017-02-17 |
| Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094) MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days - Pain | Phase 4 | Completed | Organon and Co | 337 | 2005-09-01 | 2024-08-15 |
| To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264) MK0733, simvastatin / Duration of Treatment: 12 Weeks - Hypercholesterolemia | Phase 4 | Completed | Organon and Co | 30 | 2005-05-01 | 2024-08-15 |
| Analgesic Treatment Mediated by Arcoxia (0663-093) MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days - Pain | Phase 4 | Completed | Organon and Co | 237 | 2005-04-01 | 2022-02-16 |
| Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365) MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks - Asthma, Rhinitis Allergic | Phase 4 | Completed | Organon and Co | 91 | 2005-03-18 | 2024-08-15 |
| Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks - Essential Hypertension | Phase 4 | Completed | Organon and Co | 174 | 2005-02-05 | 2024-08-15 |
| A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) MK0663; etoricoxib / Duration of Treatment: 5 Days, Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days - Acute Gout | Phase 4 | Completed | Organon and Co | 180 | 2005-01-01 | 2024-08-15 |
| Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED) MK0663, etoricoxib / Duration of Treatment: 4 weeks, Comparator: diclofenac / Duration of Treatment: 4 weeks - Chronic Low Back Pain | Phase 4 | Completed | Organon and Co | 401 | 2004-06-01 | 2022-02-15 |
| Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 477 | 2004-01-13 | 2017-04-24 |
| Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379) MK0476, montelukast sodium / Duration of Treatment: 4 Weeks, Comparator: ketotifen / Duration of Treatment: 4 Weeks - Asthma | Phase 4 | Completed | Organon and Co | 188 | 2003-09-25 | 2024-08-15 |
| A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329) MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: theophylline ER/Duration of Treatment: 16 weeks - Asthma, Allergic Rhinitis | Phase 4 | Completed | Organon and Co | 31 | 2003-02-01 | 2024-08-15 |
| Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED) MK0954, losartan potassium/Duration of Treatment: 18 weeks, Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks - Hypertension | Phase 4 | Completed | Organon and Co | 120 | 2003-02-01 | 2024-08-15 |
| An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 3 days - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 866 | 2002-10-10 | 2017-05-05 |
| First Step With Singulair® Therapy (0476-323) MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks, Comparator: Fluticasone / Duration of Treatment: 6 Weeks - Asthma | Phase 4 | Completed | Organon and Co | 399 | 2002-09-01 | 2024-08-15 |
| A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) MK0966; rofecoxib / Duration of Treatment: 24 weeks, Comparator: placebo / Duration of Treatment: 24 weeks - Adenomatous Polyposis Coli | Phase 4 | Terminated | Merck Sharp & Dohme LLC | 62 | 2002-08-06 | 2019-09-20 |
| Linear Growth Study (0476-097)(COMPLETED) MK0476, montelukast sodium / Duration of Treatment : 56 Weeks, Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks - Asthma | Phase 4 | Completed | Organon and Co | 360 | 2000-06-01 | 2024-08-14 |
| Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213) MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks - Renal Disorder | Phase 4 | Completed | Organon and Co | 97 | 2000-02-01 | 2022-02-16 |
| A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075) MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: placebo / Duration of Treatment: 16 weeks - Asthma | Phase 4 | Completed | Organon and Co | 546 | 1998-03-01 | 2022-02-02 |
Asthma (6) · Nausea (2) · Pain (2) · Vomiting (2) · Adenomatous Polyposis Coli (1) · Breast Neoplasms (1) · Cancer Pain (1) · Essential Hypertension (1) · Hypercholesterolemia (1) · Hypertension (1) · Infections (1) · Kidney Diseases (1) · Osteoarthritis (1) · Pneumonia (1) · Rhinitis, Allergic (1)
Organon and Co (14) · Merck Sharp & Dohme LLC (4)
Taiwan (1)